国家药监局:暂停进口5个日产原料药

美港电讯
17 Mar

【国家药监局:暂停进口5个日产原料药】金十数据3月17日讯,《国家药监局关于暂停进口KYOWA HAKKO BIO CO.,LTD.谷胱甘肽等5个原料药的公告》16日发布。国家药监局近期组织对日本KYOWA HAKKO BIO CO.,LTD.的Hofu工厂(生产企业英文名称:Hofu Plant of KYOWA HAKKO BIO CO.,LTD.;生产地址:1-1 Kyowa-cho, Hofu-shi, Yamaguchi, Japan)开展现场检查,发现该工厂生产的谷胱甘肽(登记号:Y20190009115)、乙酰半胱氨酸(登记号:Y20190009075)、色氨酸(登记号:Y20190009135)、苯丙氨酸(登记号:Y20190009095)、L-缬氨酸(登记号:Y20190009077)未按照批准信息组织生产,存在外购原料药进行贴签、包装或者外购粗品进行精制等情形,不符合我国《药品生产质量管理规范(2010年修订)》和药品关联审评审批有关要求。国家药监局决定,自即日起:暂停进口KYOWA HAKKO BIO CO.,LTD.的Hofu工厂生产的上述登记号的原料药,各口岸药品监督管理部门暂停发放该产品的进口通关单。

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10